CUE Key Statistics, Chart & Performance
The current stock price of CUE is 0.387 USD. In the past month the price decreased by -26.75%. In the past year, price decreased by -74.37%.
CUE Latest News, Press Relases and Analysis
CUE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.7 | 412.54B | ||
| AMGN | AMGEN INC | 15.62 | 183.97B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.89 | 122.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 18.05 | 85.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 828.43 | 55.82B | ||
| INSM | INSMED INC | N/A | 37.54B | ||
| NTRA | NATERA INC | N/A | 35.11B | ||
| BIIB | BIOGEN INC | 11.17 | 27.42B | ||
| INCY | INCYTE CORP | 17.22 | 21.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.09 | 21.69B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.86B |
Related stock screener links
About CUE
Company Profile
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. The company is headquartered in Boston, Massachusetts and currently employs 41 full-time employees. The company went IPO on 2018-01-02. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
Company Info
CUE BIOPHARMA INC
40 Guest Street
Boston MASSACHUSETTS 02139 US
CEO: Daniel R. Passeri
Employees: 41
Phone: 16179492680
CUE BIOPHARMA INC / CUE FAQ
What does CUE do?
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. The company is headquartered in Boston, Massachusetts and currently employs 41 full-time employees. The company went IPO on 2018-01-02. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
Can you provide the latest stock price for CUE BIOPHARMA INC?
The current stock price of CUE is 0.387 USD. The price increased by 5.42% in the last trading session.
Does CUE stock pay dividends?
CUE does not pay a dividend.
What is the ChartMill rating of CUE BIOPHARMA INC stock?
CUE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is CUE stock listed?
CUE stock is listed on the Nasdaq exchange.
How many employees does CUE BIOPHARMA INC have?
CUE BIOPHARMA INC (CUE) currently has 41 employees.
What is CUE BIOPHARMA INC worth?
CUE BIOPHARMA INC (CUE) has a market capitalization of 30.47M USD. This makes CUE a Nano Cap stock.
CUE Technical Analysis
CUE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CUE. Both the profitability and financial health of CUE have multiple concerns.
CUE Financial Highlights
Over the last trailing twelve months CUE reported a non-GAAP Earnings per Share(EPS) of -0.46. The EPS increased by 49.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -119.08% | ||
| ROE | -284.49% | ||
| Debt/Equity | 0.01 |
CUE Forecast & Estimates
7 analysts have analysed CUE and the average price target is 5.1 USD. This implies a price increase of 1217.83% is expected in the next year compared to the current price of 0.387.
For the next year, analysts expect an EPS growth of 44.79% and a revenue growth -14.98% for CUE